Professional
Added to YB: 2026-02-12
Pitch date: 2026-02-04
BNTX [bullish]
BioNTech SE
+2.96%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany.
Market Cap
$22.7B
Pitch Price
$107.25
Price Target
N/A
Dividend
N/A
EV/EBITDA
-19.94
P/E
-37.94
EV/Sales
2.67
Sector
Biotechnology
Category
value
Show full summary:
LMN Capital Added On Portfolio Holding: BioNTech SE
BNTX (added to position): $19B net cash (83% of $23B mkt cap), COVID vaccine biz generating low single-digit $B revs w/ 50%+ pre-tax margin. 25+ clinical programs; sold 50% BNT327 rights to BMY for $3.5B + $7.5B milestones after $1B acquisition. Down 15% in 2025 on US vaccine headwinds despite pipeline progress.
Read full article (2 min)